Fernando LARCHER LAGUZZI

Employment

• Centro de Investigaciones Energéticas Medioambientales y Tecnológicas

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (176)

• The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale
  Journal of Investigative Dermatology 2025 DOI: 10.1016/j.jid.2025.05.027
  +Save
• Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa
  Scientific Reports 2024 DOI: 10.1038/s41598-024-67398-8
  +Save
• Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa
  Journal of Investigative Dermatology 2022 DOI: 10.1016/j.jid.2021.09.018
  +Save
• CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative
  Clinical Genetics 2022 DOI: 10.1111/cge.14113
  +Save
• Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants
  JAMA Dermatology 2022 DOI: 10.1001/jamadermatol.2022.0112
  +Save
• FPR2 DNA Aptamers for Targeted Therapy of Wound Repair
  Journal of Investigative Dermatology 2022 DOI: 10.1016/j.jid.2021.12.026
  +Save
• Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis
  Matrix Biology 2022 DOI: 10.1016/j.matbio.2022.06.007
  +Save
• Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa
  Molecular Therapy 2022 DOI: 10.1016/j.ymthe.2022.04.020
  +Save
• Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors
  Molecular Therapy - Methods and Clinical Development 2022 DOI: 10.1016/j.omtm.2022.09.005
  +Save
• Non-viral delivery of CRISPR–Cas9 complexes for targeted gene editing via a polymer delivery system
  Gene Therapy 2021 DOI: 10.1038/s41434-021-00282-6
  +Save
• Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing
  Jose Bonafont, Ángeles Mencía, Esteban Chacón-Solano +11 more
  Molecular Therapy 2021 DOI: 10.1016/j.ymthe.2021.02.019
  +Save
• Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome
  Molecular Therapy - Methods & Clinical Development 2020 DOI: 10.1016/j.omtm.2020.05.031
  +Save
• Humanization of Tumor Stroma by Tissue Engineering as a Tool to Improve Squamous Cell Carcinoma Xenograft
  International Journal of Molecular Sciences 2020 DOI: 10.3390/ijms21061951
  +Save
• Advanced Statistical Techniques for Noninvasive Hyperglycemic States Detection in Mice Using Millimeter-Wave Spectroscopy
  IEEE Transactions on Terahertz Science and Technology 2020 DOI: 10.1109/TTHZ.2020.2967236
  +Save
• Early, Non-Invasive Sensing of Sustained Hyperglycemia in Mice Using Millimeter-Wave Spectroscopy
  Sensors 2019 DOI: 10.3390/s19153347
  +Save
• Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing
  Molecular Therapy 2019 DOI: 10.1016/j.ymthe.2019.03.007
  +Save
• Fibroblasts activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.
  The British journal of dermatology 2019 DOI: 10.1111/bjd.17698
  +Save
• Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa
  JCI Insight 2019 DOI: 10.1172/jci.insight.126243
  +Save
• CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient
  Molecular Therapy 2018 DOI: 10.1016/j.ymthe.2018.07.024
  +Save
• Clinically-relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing
  Human Gene Therapy 2018
  +Save